Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.29 USD | -3.32% |
|
+1.96% | +395.92% |
May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 217M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.01
x | P/E ratio 2025 * |
-
| Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66% |
1 day | -3.32% | ||
1 week | +1.96% | ||
Current month | -18.09% | ||
1 month | -31.87% | ||
3 months | +367.31% | ||
6 months | +452.27% | ||
Current year | +395.92% |
![Extreme 6.8](/images/extremecours_fleche.png)
![Extreme 6.76](/images/extremecours_fleche.png)
![Extreme 1.16](/images/extremecours_fleche.png)
![Extreme 0.66](/images/extremecours_fleche.png)
![Extreme 0.66](/images/extremecours_fleche.png)
![Extreme 0.66](/images/extremecours_fleche.png)
![Extreme 0.66](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 20-08-31 |
Founder | 66 | 01-12-31 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 22-08-07 |
Edward Benz
BRD | Director/Board Member | 78 | 17-08-31 |
Paul Manning
CHM | Chairman | 68 | 18-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 7.29 | -3.32% | 321,487 |
24-06-13 | 7.54 | -0.53% | 207,059 |
24-06-12 | 7.58 | +0.40% | 344,769 |
24-06-11 | 7.55 | +7.40% | 559,772 |
24-06-10 | 7.03 | -1.68% | 487,407 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+395.92% | 217M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- CADL Stock